Erythropoietic agents from natural sources

Alternative Therapies in Health and Medicine

Volumn 19, Issue 6, 2013, Pages 54-60

  Kim, Sung Jo ^a   Chin, Young Won ^b   Heo, Tae Hwe ^c  

^a Hoseo University   (South Korea)

^b Dongguk University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HERBACEOUS AGENT;

ANEMIA; CHEMISTRY; HUMAN; REVIEW;

ANEMIA; DRUGS, CHINESE HERBAL; ERYTHROPOIETIN; HEMATINICS; HUMANS;

EID: 84888122229     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Nabili ST, Shiel Jr WC. Anemia. MedicineNet. com Web site. http://www. medicinenet. com/anemia/article. htm. Accessed July 13, 2012.
2. Hatano R, Takano F, Fushiya S, et al. Water-soluble extracts from Angelica acutiloba Kitagawa enhance hematopoiesis by activating immature erythroid cells in mice with 5-fluorouracil-induced anemia. Exp Hematol. 2004; 32(10): 918-924.
3. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? Nephrol Dial Transplant. 2005; 20(suppl 4): iv3-iv8.
4. DeMaeyer EM. Preventing and Controlling Iron Deficiency Anemia Through Primary Health Care: A Guide for Health Administrators and Programme Managers. Geneva, Switzerland: World Health Organization; 1989.
5. Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician. 2004; 69(11): 2599-2606.
6. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int. 1997; 51(3): 622-630.
7. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002; 346(7): 469-475.
8. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996; 334(10): 630-633.
9. Krantz SB. Pure red-cell aplasia. N Engl J Med. 1974; 291(7): 345-350.
10. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004; 351(14): 1403-1408.
11. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002; 346(20): 1584-1586.
12. Tolman C, Duja S, Richardson D, et al. Four cases of pure red cell aplasia secondary to epoetin beta, with strong temporal relationships. Nephrol Dial Transplant. 2004; 19(8): 2133-2136.
13. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008; 36(12): 1573-1584.
14. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362(9392): 1255-1260.
15. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003; 4(8): 459-460.
16. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007; 25(9): 1027-1032.
17. Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009; 14(suppl 1): 43-56.
18. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ. 2004; 11(suppl 1): S37-S44.
19. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005; 6(6): 484-494.
20. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood. 1993; 81(9): 2223-2236.
21. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signaling is required for normal brain development. Development. 2002; 129(2): 505-516.
22. Tilbrook PA, Klinken SP. The erythropoietin receptor. Int J Biochem Cell Biol. 1999; 31(10): 1001-1005.
23. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001; 98(8): 4379-4384.
24. Merchionne F, Dammacco F. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. Br J Haematol. 2009; 146(2): 127-141.
25. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004; 104(7): 2073-2080.
26. Marrero MB, Venema RC, Ma H, Ling BN, Eaton DC. Erythropoietin receptoroperated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int. 1998; 53(5): 1259-1268.
27. Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998; 100(1): 79-89.
28. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003; 31(4): 290-299.
29. Johnson DL, Jolliffe LK. Erythropoietin mimetic peptides and the future. Nephrol Dial Transplant. 2000; 15(9): 1274-1277.
30. Mikhail A, Covic A, Goldsmith D. Stimulating erythropoiesis: future perspectives. Kidney Blood Press Res. 2008; 31(4): 234-246.
31. Qureshi SA, Kim RM, Konteatis Z, et al. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci U S A. 1999; 96(21): 12156-12161.
32. Bradley RR, Cunniff PJ, Pereira BJ, Jaber BL. Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient. Am J Kidney Dis. 1999; 34(2): 349-354.
33. Hatano R, Takano F, Fushiya S, et al. Water-soluble extracts from Angelica acutiloba Kitagawa enhance hematopoiesis by activating immature erythroid cells in mice with 5-fluorouracil-induced anemia. Exp Hematol. 2004; 32(10): 918-924.
34. Kim SH, Kim MJ. Biological effects of deer antler extracts on hematopoietic system. Korean J Biol Response Mod. 1993; 3: 23-30.
35. Kim SH, Lee HJ, Park JR, Kim H, Ahn, KS, Cho, DY, Choi DW. Effect of deer antler extracts from various origins and parts on the hemopoietic activity. Korean J Pharmacognosy. 2004; 35(1): 6-15.
36. Chen D, Zuo G, Li C, et al. Total saponins of Panax ginseng (TSPG) promote erythroid differentiation of human CD34+ cells via EpoR-mediated JAK2/STAT5 signaling pathway. J Ethnopharmacol. 2009; 126(2): 215-220.
37. Zuo G, Guan T, Chen D, et al. Total saponins of Panax ginseng induces K562 cell differentiation by promoting internalization of the erythropoietin receptor. Am J Chin Med. 2009; 37(4): 747-757.
38. Song JY, Han SK, Bae KG, et al. Radioprotective effects of ginsan, an immunomodulator. Radiat Res. 2003; 159(6): 768-774.
39. Takatsuki F, Miyasaka Y, Kikuchi T, Suzuki M, Hamuro J. Improvement of erythroid toxicity by lentinan and erythropoietin in mice treated with chemotherapeutic agents. Exp Hematol. 1996; 24(3): 416-422.
40. Lim J, Jeong SJ, Koh W, et al. JAK2/STAT5 signaling pathway mediates Bojungbangdocktang enhanced hematopoiesis. Phytother Res. 2011; 25(3): 329-337.
41. Takano F, Ohta Y, Tanaka T, et al. Oral administration of Ren-Shen-Yang-Rong-Tang 'Ninjin'yoeito' protects against hematotoxicity and induces immature erythroid progenitor cells in 5-fluorouracil-induced anemia. Evid Based Complement Alternat Med. 2009; 6(2): 247-256.
42. Gao QT, Cheung JK, Choi RC, et al. A Chinese herbal decoction prepared from Radix Astragali and Radix Angelicae Sinensis induces the expression of erythropoietin in cultured Hep3B cells. Planta Med. 2008; 74(4): 392-395.
43. Dong TT, Zhao KJ, Gao QT, et al. Chemical and biological assessment of a Chinese herbal decoction containing Radix Astragali and Radix Angelicae Sinensis: determination of drug ratio in having optimized properties. J Agric Food Chem. 2006; 54(7): 2767-2774.
44. Gao QT, Cheung JK, Li J, et al. A Chinese herbal decoction, Danggui Buxue Tang, prepared from Radix Astragali and Radix Angelicae Sinensis stimulates the immune responses. Planta Med. 2006; 72(13): 1227-1231.
45. Chang MS, Kim do R, Ko EB, et al. Treatment with Astragali radix and Angelicae radix enhances erythropoietin gene expression in the cyclophosphamide-induced anemic rat. J Med Food. 2009; 12(3): 637-642.
46. Chen YC, Gao YQ. Research on the mechanism of blood-tonifying effect of danggui buxue decoction [in Chinese]. Zhongguo Zhong Yao Za Zhi. 1994; 19(1): 43-45.
47. Park HR, Kim SH, Yee ST, Byun MW, Jo SK. Effect of a herb mixture (HIM-I) on the protection of the hematopoietic-immune system and self-renewal tissues against radiation damage. J Korean Soc Food Sci Nutr. 2005; 34(5): 605-612.
48. Nakamoto H, Mimura T, Honda N. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis. Hemodial Int. 2008; 12(suppl 2): S9-S14.
49. Hisha H, Yamada H, Sakurai MH, et al. Isolation and identification of hematopoietic stem cell-stimulating substances from Kampo (Japanese herbal) medicine, Juzen-taiho-to. Blood. 1997; 90(3): 1022-1030.
50. Okamura S, Shimoda K, Yu LX, et al. A traditional Chinese herbal medicine, ren-shen-yang-rong-tang (Japanese name: ninjin-yoei-to) augments the production of granulocyte-macrophage colony-stimulating factor from human peripheral blood mononuclear cells in vitro. Int J Immunopharmacol. 1991; 13(5): 595-598.
51. Fujii Y, Imamura M, Han M, et al. Recipient-mediated effect of a traditional Chinese herbal medicine, ren-shen-yang-rong-tang (Japanese name: ninjinyouei-to), on hematopoietic recovery following lethal irradiation and syngeneic bone marrow transplantation. Int J Immunopharmacol. 1994; 16(8): 615-622.
52. Motoo Y, Mouri H, Ohtsubo K, Yamaguchi Y, Watanabe H, Sawabu N. Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: a randomized controlled trial. World J Gastroenterol. 2005; 11(26): 4013-4017.
53. Son CG, Han SH, Cho JH, et al. Induction of hemopoiesis by saenghyuldan, a mixture of Ginseng radix, Paeoniae radix alba, and Hominis placenta extracts. Acta Pharmacol Sin. 2003; 24(2): 120-126.
54. Lee YW, Son CK, Cho CK. The effects of Saenghyuldan on the bone marrow failure. J Korean Oriental Med. 2001; 22: 33-45.
55. Liang QD, Gao Y, Tan HL, et al. Effects of four Si-Wu-Tang's constituents and their combination on irradiated mice. Biol Pharm Bull. 2006; 29(7): 1378-1382.
56. Liu LP, Liu JF, Lu YQ. Effects of Sheng-Mai injection on the PRPP synthetase activity in BFU-es and CFU-es from bone marrows of mice with benzene-induced aplastic anemia. Life Sci. 2001; 69(12): 1373-1379.
57. Gao RL, Xu CL, Jin JM, et al. The effects of total saponins of panax ginseng on hematopoietic progenitor cells in healthy humans and aplastic anemia patients. Chin J Integr Med. 1995; 1(1): 39-42.
58. Ohta H, Ni JW, Matsumoto K, Watanabe H, Shimizu M. Peony and its major constituent, paeoniflorin, improve radial maze performance impaired by scopolamine in rats. Pharmacol Biochem Behav. 1993; 45(3): 719-723.
59. Dai Y, But PP, Chan YP, Matsuda H, Kubo M. Antipruritic and antiinflammatory effects of aqueous extract from Si-Wu-Tang. Biol Pharm Bull. 2002; 25(9): 1175-1178.
60. Lee SE, Oh H, Yang JA, et al. Radioprotective effects of two traditional Chinese medicine prescriptions: si-wu-tang and si-jun-zi-tang. Am J Chin Med. 1999; 27(3-4): 387-396.
61. Goldberg J, Jin Q, Ambroise Y, et al. Erythropoietin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc. 2002; 124(4): 544-555.